Conroy Sun

Associate Professor
sunc@ohsu.edu

Office: 503-346-4699

Credentials: 
Stanford University, CA, USA, Postdoctoral Fellow, Radiation Oncology, 2009-2014
University of Washington, WA, USA, Senior Fellow, Neurological Surgery, 2008-2009
University of Washington, WA, USA, Ph.D. Materials Science & Engineering, 2008
University of Washington, WA, USA, B.S. Materials Science & Engineering, 2003
Additional Information: 

Selected Publications

Conroy Sun, Guillem Pratx, Colin Carpenter, Hongguang Liu, Zhen Cheng, Sanjiv Sam Gambhir, and Lei Xing, Synthesis and Radioluminescence of PEGylated Eu3+-doped Nanophosphors as Bioimaging Probes. Advanced Materials, 2011 23(24): H195-199.

Conroy Sun, Kim Du, Chen Fang, Narayan Bhattarai, Omid Veiseh, Donghoon Lee, Richard G. Ellenbogen, Buddy Ratner, and Miqin Zhang, PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physiochemical properties and function in vivo. ACS Nano, 2010 4(4): 2402-2410.

Conroy Sun, Chen Fang, Zachary Stephen, Omid Veiseh, Stacey Hansen, Donghoon Lee, Richard G. Ellenbogen, Jim Olson, and Miqin Zhang, Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine, 2008 3(4): 495-505.

Conroy Sun, Jerry S.H. Lee, and Miqin Zhang, Magnetic Nanoparticles in MR Imaging and Drug Delivery. Advanced Drug Delivery Reviews, 2008 60(11): 1252-1265.

Conroy Sun, Omid Veiseh, Jonathan Gunn, Chen Fang, Stacey Hansen, Donghoon Lee, Raymond Sze, Richard G. Ellenbogen, Jim Olson, and Miqin Zhang, In Vivo MRI Detection of Gliomas by Chlorotoxin-Conjugated Superparamagnetic Nanoprobes. Small, 2008 4(3): 372-379.

Profile Field Tabs

At OSU
Affiliated with: 
Pharmacy Professnl Instr
Faculty Type: 
Pharmaceutical Sciences
Research/Career Interests: 

My group is focused on applying nanotechnology toward unanswered problems in cancer care. In particular, we are interested in developing novel nanomaterials that serve as platforms for tumor targeted drug delivery and molecular imaging contrast agents. Here we seek to exploit the multifunctional capabilities of nanomaterials to combine conventional therapies, such as radiation and chemotherapy, to achieve a synergistic treatment response or combine treatment with medical imaging modalities for theranositic approaches, such as image-guided drug delivery. In addition, a significant portion of my research is directed toward enabling novel treatment or imaging technologies that are only possible through the use of nanotechnolgy. For example, in collaboration with colleagues at the Molecular Imaging Program at Stanford (MIPS), we have developed tumor targeted radioluminescent nanoparticles (RLNP) that serve as a centerpiece for a new in vivo imaging platform, X-ray luminescence computed tomography (XLCT). As a potential drug delivery platform, we are currently investigating the ability of RLNPs to serve as stimuli-responsive carriers for controlled release or energy mediators for deep tissue photodynamic therapy.